12,372 trials
HIV Infections · Substance Use Disorders
Primary: Feasibility of the Adherence Intervention Qualitative and Quantitive Questionnaire — 14; 14 Participants
Multiple Myeloma · Auto Stem Cell Transplant
Primary: To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in…
Colorectal Cancer
Primary: Overall Survival (OS) — 9.6; 9.2 Months — p=0.3914
Meningococcal Infection · Healthy Volunteers
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W — 4.44; 7.58; 39.0; 43.2 titer
Colorectal Cancer
Primary: Overall Survival (OS) — 7.3; 8.5 Months — p=0.4183
Trypanosomiasis, African · Gambiense Trypanosomiasis · Sleeping Sickness
Primary: Percentage of Participants With Late-stage HAT Whose Treatment Outcome Was a Success at Month 18 According to Adapted World Health Organization (WHO) Criteria — 95.2…
HIV-1-infection
Primary: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period — 0.80 proportion of…
SARS-CoV-2
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 586; 585; 627; 42 Participants
Moderate to Severe Chronic Plaque Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) — -79.87; -80.55 Percentage change from baseline
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour WI-NRS Score at Week 4 of the DB Period — -2.09; -1.27 score on a scale — p=0.0003
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 — -183.48; -138.60; -114.65 Milliliters (mL) — p=0.0222
Pulmonary Arterial Hypertension
Primary: Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body…
Leiomyoma
Primary: Pain Scores Using the VAS Questionnaire — 0.8; 1.3; 4; 6.1 score on a scale
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed…